|

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

RECRUITINGPhase 3Sponsored by Definium Therapeutics US, Inc.
Actively Recruiting
PhasePhase 3
SponsorDefinium Therapeutics US, Inc.
Started2025-01-29
Est. completion2026-11
Eligibility
Age18 Years – 74 Years
Healthy vol.Accepted
Locations15 sites
View on ClinicalTrials.gov →

NCT06809595

Summary

A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama

Eligibility

Age: 18 Years – 74 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Diagnosis of GAD per DSM-5
2. Male or female aged 18 to 74
3. HAM-A Total Score ≥20

Exclusion Criteria:

1. Certain psychiatric disorders (other than generalized anxiety disorder)
2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
4. Any clinically significant unstable illness

Conditions2

AnxietyGeneralized Anxiety Disorder

Locations15 sites

Preferred Research Partners, Inc.
Little Rock, Arkansas, 72211
Stacy Tierney501-553-9987stierney@preferredresearchpartners.com
Psychedelic Science Institute
Los Angeles, California, 90004
Keith Heinzerling310-996-8966trialadmin@psychedelicsci.com
West Los Angeles VA Medical Center
Los Angeles, California, 90073
Walter Dunn, MD, PhD310-478-3711Walter.Dunn@va.gov
Cenexel-CNS
Torrance, California, 90504
Bradenton Research Center, Inc.
Bradenton, Florida, 34205
Eric Folkens941-708-0005info@bradentonresearch.com

Browse More Trials

Anxiety trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.